近年来,开发了直接的 KRAS 抑制剂。索托雷塞是首款获得 FDA 批准用于治疗 KRAS G12C 突变非小细胞肺癌的 KRAS 抑制剂。其他突变等位基因特异性 KRAS 抑制剂,例如用于治疗 KRAS G12D 突变实体瘤的 MRTX1133,正处于临床试验中。使用 KRAS/MEK 通路抑制剂治疗散发性脑 AVM 时,可以借鉴它们在癌症背景下的使用,即...
Here, the authors investigate the mechanism underlying HER2-reactivation post KRAS-MAPK inhibition, identifying combination of MAPK and HER2 inhibition as a therapeutic strategy.doi:10.1038/s41467-024-46811-wBulle, AshenafiLiu, PengSeehra, Kuljeet...
For example, inhibition of the mitogen-activated protein kinase (MAPK) pathway, which is hyper-activated by oncogenic KRAS, sensitises cancer cells to the microtubule stabiliser paclitaxel (also known as Taxol)4–6. Moreover, lung cancer cell lines harbouring KRAS mutations are significantly more...
KRASMAPK/ERKpathwayadenomatoidodontogenictumormutationnext-generationsequencingthis study aimed to assess the frequency of KRAS mutation and its association with the presence of the MAPK / ERK signaling pathway proteins in adenomatoid odontogenic tumors.Paraffin-embedded tissue samples from 9 cases of ...
lung adenocarcinoma pancreatic ductal adenocarcinoma KRAS-driven cancer clinical trials MAPK pathway Sorry, something went wrong. Please try again and make sure cookies are enabledCited by (300) Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials 2023, Gen...
rkrasrafmapk信号通路与甲状腺癌.docx,rkrasrafmapk信号通路与甲状腺癌 近年来,甲状腺癌的发病率在中国呈上升趋势,发病率是10年前的三倍多。据复旦大学附属肿瘤医院统计, 1996年收治甲状腺癌患者为250例, 2006年上升至735例, 其中80%以上来自沿海地区。2003年上海甲状腺癌
Mitogen-activated protein kinase (MAPK) pathways are activated by several stimuli and transduce the signal inside cells, generating diverse responses including cell proliferation, differentiation, migration and apoptosis. Each MAPK casca... LH Osaki,P Gama 被引量: 0发表: 2013年研究...
We investigated the immunohistochemical expression of p53, MAPK, topoisomerase II alpha (topoII alpha) and Ki67 in ovarian serous carcinomas (OSCs) along with mutational analysis for KRAS and BRAF. Methods Eighty one cases of OSCs were reviewed and examined immunohistochemically using antibodies agains...
Treatment with KRAS G12C inhibitors induced MRAS expression, which formed a complex with SHOC2, precipitating feedback activation of MAPK signaling. Abrogation of YAP activation or MRAS induction enhanced the efficacy of KRAS G12C inhibitor treatment in vivo. These results highlight a role for ...
RMC-7977: 一种Class I PI3K抑制剂、KRAS G12D抑制剂、MAPKs抑制剂药物,由Revolution Medicines, Inc. (Revolution Medicines, Inc.)公司最早进行研发,目前全球最高研发状态为临床前,作用机制: Class I PI3K抑制剂(磷脂酰肌醇激酶I型复合体抑制剂),KRAS G12D抑制剂(KRAS